What they did

Consolidating transplant programs

DNX Corp. and Baxter Healthcare Corp. combined their organ transplantation programs into a partnership, Nextran, in which Baxter will hold a 70 percent stake and DNXX a 30 percent stake.

Nextran, which will be run as an affiliate of Baxter, will be financed initially with $20 million from Baxter and $2.5 million from Princeton, N.J.-based DNXX.